What is Lantern Pharma's market cap?

Lantern Pharma (LTRN) has a market capitalization of $35.6M and trades on NASDAQ.

Who are Lantern Pharma's competitors?

Lantern Pharma's key competitors include AbCellera, Recursion Pharmaceuticals, Schrodinger, and others. These companies compete in similar markets and product categories.

Who does Lantern Pharma partner with?

Lantern Pharma's notable partners include Actuate Therapeutics, Inc., TTC Oncology, Oregon Therapeutics, and others.

What subsidiaries does Lantern Pharma have?

Lantern Pharma's subsidiaries include Starlight Therapeutics Inc..

Where is Lantern Pharma headquartered?

Lantern Pharma is headquartered in United States of America and employs approximately 21 people. It has been publicly traded since 2020.

Lantern Pharma

LTRN

Lantern Pharma is an artificial intelligence-focused biotechnology company specializing in the discovery and development of precision oncology therapies.

Market cap

$35.6M-17.7%

Table of contents

Earnings

Q1 2026 report

May 15, 2026

EPS-$0.30Beat by $0.06

Read the full report

Next report

Aug 12, 2026 (In 2 weeks)

EPS estimate-$0.38

Competitors

By market cap

Relay Therapeutics, Inc.$4.1B+540%

Arcus Biosciences$3.5B+236%

AbCellera Biologics Inc.$1.6B+9.2%

Recursion Pharmaceuticals, Inc.$1.6B-41.6%

Schrodinger$1.1B-30.5%

Lantern Pharma$35.6M-17.7%

Allarity Therapeutics, Inc.$19.6M+15.9%

Aptevo Therapeutics$5.2M-99.3%

By revenue growth

AbCellera Biologics Inc.+243%

Arcus Biosciences+67.4%

Relay Therapeutics, Inc.+39.0%

Recursion Pharmaceuticals, Inc.+11.1%

Schrodinger+10.6%

By net margin

Schrodinger-68.49%+4.4pp

Arcus Biosciences-156.36%+121pp

AbCellera Biologics Inc.-181.75%+544pp

Recursion Pharmaceuticals, Inc.-842.93%+118pp

Relay Therapeutics, Inc.-2,554.14%+1,787pp

Profile

Lantern Pharma is an artificial intelligence-focused biotechnology company specializing in the discovery and development of precision oncology therapies. The company leverages its proprietary RADR® platform, which integrates big data and machine learning, to identify genomic signatures that predict drug response and to rescue or develop small molecule drug candidates. Its core value proposition lies in reducing the time and cost of oncology drug development by targeting specific patient populations most likely to benefit from its therapies.

Competitive position

Lantern Pharma is a pioneer in AI-driven drug rescue, utilizing a massive oncology-focused dataset to de-risk clinical trials and advance therapies at a fraction of traditional costs.

GeographiesUnited States, Japan, Taiwan, European Union

Customer segmentsBiopharmaceutical Companies, Research Institutions, Clinical Trial Sponsors

Business modelDrug Development, Licensing, SaaS, Research Services

SuppliersContract Manufacturing Organizations (CMOs), Public and proprietary genomic databases, Cloud computing infrastructure providers, Academic research institutions

CustomersPharmaceutical companies, Biotechnology firms, Oncology researchers, Clinical trial participants

CountryUnited States of America

Listed2020

Employees21.0

CEOPanna Sharma

SectorHealthcare

IndustryBiotechnology

Websitelanternpharma.com

FilingsSEC EDGAR

Questions, answered.

What is Lantern Pharma's market cap?: Lantern Pharma (LTRN) has a market capitalization of $35.6M and trades on NASDAQ.
Who are Lantern Pharma's competitors?: Lantern Pharma's key competitors include AbCellera, Recursion Pharmaceuticals, Schrodinger, and others. These companies compete in similar markets and product categories.
Who does Lantern Pharma partner with?: Lantern Pharma's notable partners include Actuate Therapeutics, Inc., TTC Oncology, Oregon Therapeutics, and others.
What subsidiaries does Lantern Pharma have?: Lantern Pharma's subsidiaries include Starlight Therapeutics Inc..
Where is Lantern Pharma headquartered?: Lantern Pharma is headquartered in United States of America and employs approximately 21 people. It has been publicly traded since 2020.